Background: Dyslipidemia is a common co-morbid condition in participants with T2DM. AACE guidelines advocate moderate to high intensity statins in T2DM unless contraindicated.

Objective: Assess evaluation practices and treatment patterns for dyslipidemia with statin intensity usage in the T2DM population as per AACE guidelines.

Methods: Sub-analysis of prospective, cross sectional, observational LEADD study in T2DM participants, conducted at 226 sites Participants stratified basis risk status and mean LDL was compared to recommended LDL levels as per AACE guidelines. “n”=number of participants analyzed for each parameter.

Results: Total of 4002 participants were evaluated and had mean (±SD) LDL - C levels of 117.7 ± 37.66 mg/dl. AACE Risk stratification with available data (n = 3538/4002) of participants was conducted on stratification 0.3% (n = 11/3538) participants were in high risk, 87.0% (n = 3077/3538) in very high risk and 12.7% (450/3538) in extreme risk category. Mean(±SD) LDL - C was 116.8 (± 36.41), 118.1 (±38.04) and 118.4 (± 41.39) mg/dl as against goal of <100, <70 and <55mg/dl for high risk, very high risk and extreme risk groups. 77.5% (n = 1523/1964) participants evaluated for dyslipidemia received Rosuvastatin. Percentage participants not on LDL- C goal were 54.54%, 89.88% and 94.77% in high risk, very high risk and extreme risk. 87.44% (n = 1962/2244), and 77.69% (n = 282/363 in very high risk and extreme risk group did not receive moderate to high intensity statin as recommended by AACE.

Conclusion: AACE guidelines adherence for evaluation and management of diabetic dyslipidemia is sub-optimal in study population. Although population falling in very high to extreme risk, they were not treated with moderate to high intensity statins. Reasons for these findings require further research.


A. Unnikrishnan: Other Relationship; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Dr. Reddys Laboratories, Eli Lilly and Company, Eris Pharmaceuticals, Ipca Laboratories Ltd., MSD, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Sanofi. A.K. Das: None. B.D. Saboo: None. S. Kalra: None. V. Ayyar: None. M.H. Tiwaskar: None.


Diabetes Care India; Dr. Reddy's Laboratories

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at